Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population

Annals of Clinical Biochemistry

Volumn 41, Issue 3, 2004, Pages 201-206

  McArdle, Peter A ^a   Pollock, M A ^b   Wallace, A M ^a   McMillan, D C ^a   Crooks, J E ^b   Underwood, M A ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; UNITED KINGDOM;

BIOLOGICAL MARKERS; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 2442586737     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456304323019569     Document Type: Article

References (12)

1. CancerStats 2002, Cancer Research UK, London www.cancerresearchuk.org
2. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in the serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
3. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44: 1216-23
4. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. Free and total prostate-specific antigen in a screened population. Br J Urol 1997; 79: 756-62
5. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998; 279: 1542-7
6. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8
7. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, et al. Complexed prostate specific antigen provides significant enhancement of specificity when compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
8. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167; 2017-23
9. Babian RJ, Kojima M, Ramirez EI, Johnston D. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 1996; 156: 432
10. Masters JG, Keegan PE, Hildreth AJ, Greene DRJ. Free/total serum prostate-specific antigen ratio: How helpful is it in detecting prostate cancer? Br J Urol 1998; 81: 419-23
11. Klingler HC, Woo H, Rosario D, Cutinha PE, Anderson, J, Ward AM, Chapple CR. The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. Br J Urol 1998; 82: 393-7
12. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62